This information was published on 2025-02-27T04:19:13 for IP Right Filed Published.
| Field | Value |
| (210) | 2525688 (IR 1841437) |
| (220) |
30 Sep 2024
|
| (300) |
US, 01 Apr 2024, 98478168
|
| (511) (510) |
Class 5
Pharmaceutical preparations for use in the treatment of autoimmune diseases and disorders, autoinflammatory diseases and disorders, alloimmune diseases and disorders, allergic diseases and disorders, autoimmune diseases and disorders, acute illness, diabetes, stroke, inflammation and inflammatory disease, respiratory and infectious diseases, acute respiratory distress illness, immunological disorders and metabolic diseases; autologous therapies (terms considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); allogeneic therapies (terms considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); virotherapies (terms considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); human cells for medical purposes; cells for medical therapy use; cultured human cells for therapeutic use. |
| (540) | GENTIBIO |
| (550) | Word |
| (730) |
GentiBio, Inc.
|
Find out more about publications on the About page.